Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
Launched by KOREA UNIVERSITY · Aug 25, 2009
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
In patients who are suspected to have variceal bleedings, pharmacologic therapy with vasoactive drugs such as terlipressin, somatostatin, and octreotide is recommended as soon as possible, even before endoscopy. However, it is still unclear whether the efficacies of these drugs are same or not. This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • liver cirrhosis
- • age between 16 and 75 years
- • Patients who have upper GI bleeding symptoms (hematemesis or melena) within 24 hours before enrollment
- • Patients whose systolic blood pressure \<100 mmHg or pulse rate \>100/min at the enrollment
- • Patients who were not performed endoscopic or pharmacologic therapy for varices
- • Signed informed consent
- Exclusion Criteria:
- • Pregnancy
- • Positive anti-HIV Ab
- • A history of severe side-effects or contraindications to study drugs
- • Severe cardiovascular diseases: acute myocardial infarction, A-V block, congestive heart failure, ischemic heart disease, hypertension (systolic blood pressure \>170 mmHg or diastolic pressure \>100 mmHg)
- • Chronic renal failure
- • Hepatocellular carcinoma with protal vein thrombosis
- • Coexisting malignancy except hepatocellular carcinoma
About Korea University
Korea University is a prestigious academic institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Korea University leverages its extensive resources and expertise to conduct innovative studies aimed at enhancing healthcare outcomes. The university fosters collaboration among leading researchers, medical professionals, and industry partners to drive the development of new therapies and interventions. With a focus on ethical standards and patient safety, Korea University is dedicated to contributing valuable insights to the scientific community and improving the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Soon Ho Um, Prof
Principal Investigator
Korea University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials